NYSE:LLY - New York Stock Exchange, Inc. - US5324571083 - Common Stock - Currency: USD
Taking everything into account, LLY scores 7 out of 10 in our fundamental rating. LLY was compared to 194 industry peers in the Pharmaceuticals industry. LLY scores excellent on profitability, but there are some minor concerns on its financial health. LLY is not priced too expensively while it is growing strongly. Keep and eye on this one!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 12.42% | ||
ROE | 70.45% | ||
ROIC | 27.17% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 40.25% | ||
PM (TTM) | 22.66% | ||
GM | 81.7% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.19 | ||
Debt/FCF | N/A | ||
Altman-Z | 7.62 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.37 | ||
Quick Ratio | 1.06 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 55.57 | ||
Fwd PE | 25.83 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 35.57 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 0.79% |
NYSE:LLY (7/21/2025, 2:40:08 PM)
764.661
-7.05 (-0.91%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 0.79% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 55.57 | ||
Fwd PE | 25.83 | ||
P/S | 14.79 | ||
P/FCF | N/A | ||
P/OCF | 77.78 | ||
P/B | 45.97 | ||
P/tB | 181.99 | ||
EV/EBITDA | 35.57 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 12.42% | ||
ROE | 70.45% | ||
ROCE | 33.25% | ||
ROIC | 27.17% | ||
ROICexc | 28.73% | ||
ROICexgc | 36.37% | ||
OM | 40.25% | ||
PM (TTM) | 22.66% | ||
GM | 81.7% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.19 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 1.6 | ||
Cap/Depr | 578.92% | ||
Cap/Sales | 21.61% | ||
Interest Coverage | 250 | ||
Cash Conversion | 43.23% | ||
Profit Quality | N/A | ||
Current Ratio | 1.37 | ||
Quick Ratio | 1.06 | ||
Altman-Z | 7.62 |